Clinical trials: Ulcerated Melanomas

Ulcerated Melanomas

Adjuvant PEG Intron in Ulcerated Melanoma

• Unknown status
• Age: 18 to 70 years
• Phase 3
• Injection or infusion

Patients with an ulcerated melanoma with Breslow >1 mm, N0M0 have a significantly higher risk for relapse than patients with a non-ulcerated primary and about a 40-50% chance of developing stage IV disease to which they will…

Trial name

NCT01502696

Testing

PEG IFN alfa-2b

Where

58 sites in Austria, Belgium and 10 more

Volunteers

1,200 people

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC